… to control SARS-CoV-2 in humans and could represent a catastrophe for conservation of …
non-human primates [8,25]. Thus, the current study investigated evidence for SARS-CoV-2 …

… Although we developed this model to analyze SARS-CoV-2 in non-human primates, our
results showed many similarities with patterns previously noted in humans. Multiple studies …

… ) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history
of SARS-CoV-1 … SARS-CoV-2-reactive human monoclonal antibodies from plasmablasts or …

… The challenge dose was chosen to induce viral loads similar to or higher than those detected
in nasal secretions of humans after SARS-CoV-2 infection (27). The primary efficacy end-…

… SARS-CoV-2 in humans. COH04S1 likely confers protection through different immune
mechanisms than the mRNA and Ad26 vaccines and may therefore be particularly valuable as a …

… the efficacy of current SARS-CoV-2 vaccines against … SARS-CoV-2 strains 6,22,23 .
Additionally, it was reported that sera from mRNA-1273-immunized human and nonhuman primates …

… ) consisting of human IgG Fc fragment-conjugated RBD (RBD-Fc) of the original SARS-CoV-…
This CF501/RBD-Fc vaccine could elicit extremely potent nAb responses against SARS-CoV…

… isotype control mAb or AZD7442 as prophylaxis 3 days prior to SARS CoV-2 challenge. …
macaques receiving AZD7442 or AZD7442-YTE as treatment 1 day after SARS CoV-2 infection. …

… to SARS-CoV-2 infection in humans have and will continue to accelerate this development
process. Several animal models including mice, hamsters, ferrets, and non-human primates …

… in both mice and humans. … non-human primates (NHPs) and found that it could also induce
neutralizing antibodies and, most importantly, accelerate the viral clearance upon SARS-CoV-…